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B

-cell non-Hodgkin lymphoma (B-NHL) encompasses multiple clinically and phenotypically distinct subtypes of malignancy with
unique molecular etiologies. Common subtypes of B-NHL, such as
diffuse large B-cell lymphoma, have been comprehensively interrogated
at the genomic level, but rarer subtypes, such as mantle cell lymphoma,
remain less extensively characterized. Furthermore, multiple B-NHL subtypes have thus far not been comprehensively compared using the same
methodology to identify conserved or subtype-specific patterns of
genomic alterations. Here, we employed a large targeted hybrid-capture
sequencing approach encompassing 380 genes to interrogate the genomic landscapes of 685 B-NHL tumors at high depth, including diffuse large
B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and
Burkitt lymphoma. We identified conserved hallmarks of B-NHL that
were deregulated in the majority of tumors from each subtype, including
frequent genetic deregulation of the ubiquitin proteasome system. In
addition, we identified subtype-specific patterns of genetic alterations,
including clusters of co-occurring mutations and DNA copy number
alterations. The cumulative burden of mutations within a single cluster
were more discriminatory of B-NHL subtypes than individual mutations,
implicating likely patterns of genetic cooperation that contribute to disease etiology. We therefore provide the first cross-sectional analysis of
mutations and DNA copy number alterations across major B-NHL subtypes and a framework of co-occurring genetic alterations that deregulate genetic hallmarks and likely cooperate in lymphomagenesis.
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Introduction
Non-Hodgkin lymphomas (NHL) are a heterogeneous
group of lymphoid malignancies that predominantly arise
from mature B cells (B-NHL). Although mature B-cell neoplasms encompass 38 unique diagnostic subtypes, over
85% of cases fall within only seven histologies.1,2 Recent
next-generation sequencing studies have shed light onto the
key driver mutations in many of these B-NHL subtypes; for
example, large studies of diffuse large B-cell lymphoma
(DLBCL) have led to proposed genomic subtypes that have
unique etiologies.3-5 However, many less common NHL
subtypes such as mantle cell lymphoma (MCL) have not
been as extensively characterized.6,7 Furthermore, until
recently3,4 genetic alterations have been considered in a
binary fashion as either driver events, which directly promote disease genesis or progression, or passenger events,
which have little or no impact on disease biology. In contrast to this principle, most B-NHL do not result from a single dominant driver but instead result from the serial acquisition of genetic alterations that cooperate in lymphomagenesis.8 The genetic context of each mutation likely determines its oncogenic potential, and groups of mutations
should therefore be considered collectively rather than as
singular events. For example, the ‘C5’ and ‘MCD’ clusters
identified in DLBCL by Chapuy et al. and Schmitz et al.,
respectively, are characterized by the co-occurrence of
CD79B and MYD88 mutations.3,4 In animal models, the
Myd88 L252P mutation (equivalent to human L265P) was
found to promote downregulation of surface IgM and a
phenotype resembling B-cell anergy.9 However, this effect
could be rescued by the Cd79b mutation, showing that
these co-occurring mutations cooperate.9 The characterization of other significantly co-occurring genetic alterations
are therefore likely to reveal additional important cooperative relationships. We approached this challenge by performing genomic profiling of 685 B-NHL across different
subtypes. Through this cross-sectional analysis we characterized genomic hallmarks of B-NHL and sets of significantly co-associated events that likely represent subtype-specific cooperating genetic alterations. This study therefore provides new insight into how co-occurring clusters of genetic
alterations may contribute to molecularly and phenotypically distinct subtypes of B-NHL.

microarrays10-12 (n=284). An additional series of 223 formalin-fixed
paraffin-embedded tumors were provided by other centers.
Samples were de-identified and accompanied by the patients’
diagnosis from the medical records, plus overall survival time and
status when available. Medical record diagnosis was used in all
cases except for those with fluorescence in situ hybridization
(FISH) showing translocations in MYC and BCL2 and/or BCL6,
which were amended to DHL. Sequencing results for a subset of
52 BL tumors were described previously.13 All MCL samples were
either positive for CCND1 translocation by FISH or positive for
CCND1 protein expression by immunohistochemistry, depending
on the diagnostic practices of the contributing institution.

Next-generation sequencing
A total of 500-1000 ng of genomic DNA was sonicated using a
Covaris S2 Ultrasonicator, and libraries prepared using KAPA
Hyper Prep Kits (Roche) with TruSeq Adapters (Bioo Scientific)
and a maximum of eight cycles of polymerase chain reaction
(average of 4 cycles). Libraries were qualified by TapeStation 4200,
quantified by Qubit and 10- to 12-plexed for hybrid capture. Each
multiplexed library was enriched using our custom LymphoSeq
panel encompassing the full coding sequences of 380 genes that
were determined to be somatically mutated in B-cell lymphoma
(Online Supplementary Table S2, Online Supplementary Methods), as
well as tiling recurrent translocation breakpoints. Enrichments
were amplified with four to eight cycles of polymerase chain
reaction and sequenced on a single lane of an Illumina HiSeq
4000 with 100PE reads in high-output mode at the Hudson
Alpha Institute for Biotechnology or the MD Anderson
Sequencing and Microarray Facility. Variants were called using
our previously validated ensemble approach,13,14 germline polymorphisms were filtered using dbSNP annotation and the EXAC
dataset containing 60,706 healthy individuals,15 and significantly
mutated genes were defined by MutSig2CV.16 Copy number
alterations (CNA) identified by CopyWriteR,17 which was validated using three FL tumors with matched Affymetrix 250K SNP
array (Online Supplementary Figure S2), and significant DNA CNA
were determined by GISTIC2.18 Translocations were called using
FACTERA,19 which we previously validated against MYC
translocation status determined by FISH.20 Mutation and CNA
data are publicly viewable through cBioPortal: https://www.cbioportal.org/study/summary?id=mbn_mdacc_2013. Matched gene
expression microarray data are available through the Gene
Expression Omnibus, accession GSE132929. For further details,
refer to the Online Supplementary Methods.

Methods
Results
An overview of our approach is shown in Online Supplementary
Figure S1. For detailed methods, please refer to the Online
Supplementary Information.

Tumor DNA samples
We collected DNA from 685 B-NHL tumors, including 199 FL,
196 MCL, 148 DLBCL, 107 BL, 21 high-grade B-cell lymphoma
not otherwise specified (HGBL-NOS), and 14 high-grade B-cell
lymphoma with MYC, BCL2 and/or BCL6 rearrangement (DHL)
(Online Supplementary Table S1). All samples were archival and deidentified. The study was approved by the institutional review
board of the University of Nebraska Medical Center (203-15-EP)
and performed in accordance with the Declaration of Helsinki. A
total of 462 samples were obtained from the University of
Nebraska Medical Center, and were prioritized for inclusion in
this study if they had previously undergone pathology review and
been interrogated by Affymetrix U133 Plus 2.0 gene expression
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Identification of significantly mutated genes and
structural alterations
We used a 380-gene custom targeted sequencing
approach, LymphoSeq, to interrogate the genomes of 685
mature B-NHL, sequencing to an average depth of 578X
(minimum, 101X; maximum, 1785X) (Online Supplementary
Table S1) for a total yield of 1.81 Tbp. Somatic nucleotide
variants and small insertions/deletions were identified
using an ensemble approach that we have previously validated14 (Online Supplementary Table S3) and significantly
mutated genes were identified using MutSig2CV (Online
Supplementary Table S4). Matched germline DNA was available from purified T cells of 20 tumors (11 FL and 9 MCL)
and sequenced to validate the filtering of germline variants;
0/632 variants called within these tumors were identified in
the matched germline samples, which indicates that the fil691
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tering of germline variants was effective. Genes that were
significantly mutated in the full cohort or in any one of the
four subtypes with more than 100 tumors (BL, DLBCL, FL,
and MCL) were included, as well as frequently mutated
genes that are targets of activation-induced cytidine deaminase (AID) (Figure 1, Online Supplementary Table S5).
Predictably, the frequency of AID-associated mutations
was higher among germinal center-derived lymphomas
(BL, DLBCL, FL), but also accounted for 7.6% of all coding
and non-coding mutations in MCL (Online Supplementary
Table S6). The mutational burden calculated from our targeted region correlated significantly with that from the
whole exome (Online Supplementary Figure S3A) and was
significantly higher in DLBCL and other high-grade tumors
than in FL and MCL (Figure 1, Online Supplementary Figure
S3B).
The hybrid capture probes utilized in our design also targeted recurrent breakpoint regions in the immunoglobulin
heavy- and light-chain loci, and recurrent breakpoints in or
near the BCL2, MYC and BCL6 genes, and translocations
were called using a method that detects discordantly
mapped reads19 (Figures 1 and 2A). Our prior validation of
this approach in cases with matched FISH data for MYC
showed that it is 100% specific, but only ~40% sensitive
for translocation detection.13 This limit of sensitivity likely
varies for different genes depending on how well the breakpoints are clustered into hotspots that are targeted by our
capture probes. Nonetheless, we observed a significantly
higher fraction of BCL6 translocations (57% [27/47]) partnered to non-immunoglobulin loci (e.g., CIITA, RHOH,
EIF4A2, and ST6GAL1) (Online Supplementary Table S7)
compared to BCL2 (1% [1/114]) and MYC (5% [2/38])
translocations (Figure 2A; Fisher P-value <0.001). These
were more frequent in FL (88% [15/17] of BCL6 translocations) than in DLBCL (39% [9/23] of BCL6 translocations),
presumably because the two immunoglobulin loci in FL are
either translocated with the BCL2 gene or functioning in
immunoglobulin expression.21 We also employed off-target
reads to detect DNA CNA in a manner akin to low-pass
whole genome sequencing, identified significant peaks of
copy gain and losses using GISTIC218 (Figures 1 and 2A,
Online Supplementary Figure S4, Online Supplementary Tables
S8 and S9), and defined the likely targets of these CNA by
integrative analysis of matched gene expression profiling
data from 290 tumors (Figure 2B, C, Online Supplementary
Figure S4, Online Supplementary Tables S10 and S11). This
identified known CNA targets, including but not limited to
deletion of TNFAIP3 (6q24.2),22 ATM (11q22.3),23 B2M
(15q15.5),24 and PTEN (10q23.21),25 and copy gain of REL
and BCL11A (2p15), and TCF4 (18q23).26 In addition, we
identified novel targets such as deletion of IBTK (6q14.1),
UBE3A (11q22.1) and FBXO25 (8p23.3), and copy gain of
ATF7 (12q13.13), UCHL5 (1q31.3), and KMT2A (11q23.3).
Importantly, the frequency of DNA CNA in the target
genes identified by next-generation sequencing-based
analysis significantly correlated with those derived from
single nucleotide polymorphism microarray-based measurements in independent cohorts of BL, DLBCL, FL and
MCL tumors from previously published studies6,20,26-30
(Online Supplementary Figure S5), providing validation for
the accuracy of this approach. The CNA peaks, defined as
the smallest and most statistically significant region, included multiple genes that were significantly mutated (Figure
2D) as well as other genes for which we detected mutations
at lower frequencies that were not significant by
692

MutSig2CV (POU2AF1, TP53BP1, FAS, PTEN). Deletions of
ATM, B2M, BIRC3 and TNFRSF14 significantly co-associated with mutations of these genes, suggesting that these are
complementary mechanisms contributing to biallelic inactivation.

Conserved functional hallmarks of B-cell non-Hodgkin
lymphoma
To understand key hallmarks that are deregulated by
genetic alterations, we performed hypergeometric enrichment analysis of genes targeted by recurrent mutations and
DNA CNA using DAVID31 (Online Supplementary Table S12).
This revealed a significant enrichment of multiple overlapping gene sets that could be summarized into hallmark
processes associated with epigenetics and transcription
(Figure 3A), apoptosis and proliferation (Figure 3B), signaling (Figure 3C), and ubiquitination (Figure 3D). One or
more genes within these hallmarks was altered in the
majority (>50%) of tumors from each of the four major histologies included in this study. Genes annotated in epigenetic-associated gene sets were altered in 72%, 70%, 93%
and 50% of BL, DLBCL, FL, and MCL, respectively, whereas genes annotated in transcription-associated gene sets
were altered in 94%, 91%, 95% and 88% of BL, DLBCL,
FL, and MCL, respectively. However, there is an extremely
high degree of functional overlap between epigenetics and
transcriptional regulation, as well as overlapping gene set
annotations for many genes, leading us to consider these
categories collectively as a single hallmark. Collectively,
genes involved in epigenetics and transcription were mutated in 94% of BL, 92% of DLBCL, 96% of FL and 89% of
MCL, and included those that encode proteins that catalyze
post-translational modifications of histones (KMT2D,
CREBBP, EZH2, EP300, WHSC1, ASHL1L, KMT2A), components of the BAF chromatin remodeling complex
(ARID1A, SMARCA4, BCL7A, BCL11A), linker histones
(HIST1H1E, HIST1H1C, HIST1H1B), and transcription factors (BCL6, IRF4, IRF8, TCF3, TCF4, MYC, REL, PAX5,
POU2AF2, FOXO1, CIITA). Genes with a role in signaling
included those involved in B-cell receptor signaling (CD79B,
ID3, TCF3, TCF4, RFTN1), NFB (TNFAIP3, CARD11,
NFKBIE), NOTCH (NOTCH1, NOTCH2), JAK/STAT
(SOCS1, STAT6), PI3K/mTOR (FOXO1, ATP6V1B2,
APT6AP1) and G-protein signaling (GNA13, GNAI2). The
CD79A and BCL10 genes were also mutated at a lower frequency that was not significant by MutSig2CV (Online
Supplementary Figure S6A, B). Among these, the RFTN1 gene
(Online Supplementary Figure S6C) is a novel recurrently
mutated gene that was mutated in 7.4% of DLBCL and
encodes a lipid raft protein that is critical for B-cell receptor
signaling.32
Deregulation of the ubiquitin proteasome system is
important in many cancers,33 but is not a well-defined hallmark of B-NHL. However, one or more genes with a role in
regulating ubiquitination was genetically altered in 61% of
BL, 79% of DLBCL, 61% of FL and 82% of MCL (Figure
3D). These included previously described genetic alterations such as amplification of MDM2,34 deletions of
TNFAIP3,35 CUL4A,36 and RPL5,36 and mutations of KLHL6,37
DTX1,38 UBR5,39 SOCS1,40 and BIRC3.6 In addition, we identified novel targets such as recurrent deletions of IBTK, a
negative regulator of Bruton tyrosine kinase,41 and somatic
mutation of CDC27 in 14% of MCL, which encodes an E3
ligase for CCND1.42 Therefore, common hallmark processes are targeted by genetic alterations in the majority of
haematologica | 2022; 107(3)
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Figure 1. Recurrently mutated genes in subtypes of B-cell non-Hodgkin lymphoma. An oncoplot shows significantly mutated genes, DNA copy number alterations
(CNA) and translocations (Tx.) across our cohort of 685 B-cell non-Hodgkin lymphoma tumors. Mutation types and frequencies are summarized for each gene/CNA
on the right, and the mutational burden for each case is shown at the top. DHL: double-hit lymphoma; THL: triple-hit lymphoma; HGBL-NOS: high-grade B-cell lymphoma not otherwise specified; BL: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma.
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Figure 2. Structural alterations in subtypes of B-cell non-Hodgkin lymphoma. (A) A circos plot shows translocations of MYC (purple), BCL2 (orange) and BCL6 (green)
genes, and GISTIC tracks of DNA copy number gains (red) and losses (blue). (B, C) Volcano plots of integrative analysis results showing the changes in gene expression
of genes within peaks of DNA copy number gain (B) or loss (C). A positive T-test score indicates increased expression in tumors with a given copy number alteration,
and vice versa. Significantly expressed genes with the correct directionality are highlighted in the shaded areas. (D) Oncoplots show the overlap of structural alterations and mutations that target the same genes. P-values are derived from a Fisher exact test (ns: not significant).

major B-NHL subtypes, including genes with a role in regulating protein ubiquitination.

Subtype-specific patterns of genetic alterations
We formally tested the over- or under-representation of
recurrent genetic alterations in each of the four subtypes
with more than 100 samples (BL, DLBCL, FL, MCL), compared to all other tumors in the study (Figure 4, Online
Supplementary Table S13). We observed some interesting
patterns within hallmark characteristics that differ between
subtypes. An illustrative example of this is the alternative
avenues for BAF complex perturbation between different
histologies (Figure 5). Specifically, mutations of the SMARCA4 (aka. BRG1) component of the ATPase module were
significantly enriched in BL (24%) compared to other subtypes (4%, Q-value <0.001), while mutations of the BCL7A
component of the ATPase module were significantly
enriched in FL (11%) compared to other subtypes (4%, Qvalue=0.007). In contrast, mutations of ARID1A were frequent in both BL (19%) and FL (15%), and DNA copy number gains of BCL11A were frequent in both DLBCL (28%)
and FL (22%). The BAF complex is therefore a target of
recurrent genetic alterations, as previously suggested,43 but
the manner in which this complex is perturbed varies
between B-NHL subtypes (Figure 5). Similar disease-specific patterns were also observed for signaling genes; for
example, TCF3 and ID3 have important functions in normal
germinal center B cells (GCB),44 but mutations of these
genes are specifically enriched within BL and are rarely
found in the other GCB-derived malignancies, DLBCL and
FL. Similarly, the ATP6AP1 and ATP6V1B2 genes that function in mTOR signaling45,46 are specifically mutated in FL,
and the DUSP2 gene which inactivates ERK1/247 and
694

STAT348 is specifically mutated in DLBCL. The disease-specific patterns of genetic alterations therefore reveal subtle
but important differences in how each subtype of B-NHL
perturbs hallmark features.

Clusters of co-associated genomic alterations in
subtypes of B-cell non-Hodgkin lymphoma
We next defined how each genetic alteration co-associated with or mutually excluded other genetic alterations by
pairwise assessments using false-discovery rate (FDR)-corrected Fisher tests (Online Supplementary Table S14). A
matrix of the transformed FDR Q-values (-logQ) was used
for unsupervised hierarchical clustering to identify clusters
of co-associated genetic alterations. Together with patterns
of disease-specificity, unsupervised clustering revealed clear
groupings of co-associated events for BL, DLBCL, FL and
MCL (Figure 4). We identified a single cluster of significantly co-associated genetic alterations that was specifically
enriched in BL (Cluster 1), including mutations and translocations of MYC, and mutations of CCND3, SMARCA4,
TCF3 and ID3 which have been previously reported in BL.4
A single cluster was significantly enriched in MCL (Cluster
7), with a high frequency of ATM mutations and deletions,
as well as other DNA CNA. Other mutations that were not
significantly co-associated were also enriched in MCL
(Cluster 6), such as those in WHSC1, NOTCH1, NOTCH2,
BCOR and UBR5, although statistical assessment of coassociation may be hampered in this context by the low frequencies of mutations within these genes. A single cluster
was also enriched in FL (Cluster 4), with a high prevalence
of KMT2D, BCL2, CREBBP, EZH2 and TNFRSF14 mutations and BCL2 translocations. The genes within Cluster 4
also significantly overlapped with the previously reported
haematologica | 2022; 107(3)
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C3, EZB and BCL2 clusters from prior whole exome
sequencing studies of DLBCL3,49,50 (Fisher test P-values:
P=0.0006, P=0.0148 and P=0.0173, respectively). Two clusters (Clusters 2 and 3) were enriched in DLBCL, with lower
frequencies of mutations in a larger number of genes, in line
with the genetic heterogeneity of this disease.3,4 Cluster 2
includes co-associated genetic alterations that overlapped
with the previously described C5, MCD, and MYD88 clusters3,4 (Fisher P-values: P=0.0004, P=0.0002 and P=0.0007,
respectively) including CD79B, MYD88 and TBL1XR1
mutations. Genes within Cluster 3 overlapped in a statistically significant manner with those in the previously

described C4 and SOCS1/SGK1 clusters (Fisher P-values:
P=0.0002 and P=0.0074, respectively), including SGK1,
TET2, SOCS1 and histone H1 genes. We also identified a
cluster consisting of TP53 mutations and multiple CNA
(Cluster 5) similar to the genetically complex C2/A53 subtype reported in DLBCL;3,49 however, the overlap of features
within these clusters could not be formally assessed due to
differing annotations. The CNA captured in this cluster
were variably represented across B-NHL subtypes, but
were most frequent in DLBCL. B-NHL subtypes therefore
harbor characteristic clusters of co-associated genetic alterations that likely cooperate in disease etiology.

A
Figure 3. Figure continued on the following
page.

B
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Figure 3. Functional enrichment of targets of somatic mutations and DNA
copy number alterations. Genes targeted by somatic mutation and/or DNA
copy number alteration were evaluated
for enrichment in curated gene sets,
and significant gene sets subsequently
grouped according to overlapping gene
set membership and functional similarity. In addition to genes assigned by
DAVID (purple), some genes were manually curated into hallmark processes
by literature review of their function
(pink). Enriched gene sets could be
summarized into four major hallmark
processes, including (A) epigenetic and
transcriptional control of gene expression, (B) regulation of apoptosis and
proliferation, (C) regulation of signaling
pathway activity, and (D) regulation of
protein ubiquitination. The frequency of
each genetic alteration is shown for
each of the four major histologies
included in this study, and the fraction
of tumors in each histology bearing
genetic alterations of one or more of the
genes is summarized by a pie graph at
the bottom for each hallmark. BL:
Burkitt lymphoma; DLBCL: diffuse large
B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma;
HMT, histone methyltransferase. HAT,
histone acetyltransferase. DDR, DNA
damage response. BCR, B-cell receptor.

D

Combinations of genetic alterations define molecular
subtypes of B-cell non-Hodgkin lymphoma
Our data have revealed statistical enrichment of individual genetic alterations in subtypes of B-NHL, and pairwise
relationships between different genetic alterations that
define clusters of subtype-specific events. To validate and
expand upon these observations we leveraged gene expression microarray data from 284 tumors that underwent
pathology review and were profiled as part of prior studies.10-12 We utilized BL, DHL, HGBL-NOS and DLBCL
tumors to perform classification into molecularly-defined
BL (mBL) and non-mBL using a Bayesian classifier with previously described marker genes,51 and subclassified nonmBL into activated B-cell (ABC)-like and GCB-like subtypes
as we have described previously26 (Online Supplementary
Figure S7). We evaluated the frequency of cumulative (2)
genetic alterations within each cluster among mBL, ABClike DLBCL, GCB-like DLBCL, FL and MCL (Figure 6). This
showed that Cluster 1 genetic alterations that were individually enriched in BL are cumulatively acquired in mBL, with
87% of tumors having 2 of these alterations compared to
only 22% of GCB-like DLBCL. Similarly, Cluster 4 and
Cluster 7 alterations were cumulatively acquired in 77%
and 72% of molecularly-annotated FL and MCL, respectively. Cluster 4 mutations were also cumulatively acquired
in 51% of GCB-like DLBCL, likely capturing the
C3/EZB/BCL2 subtype that has genetic similarities to FL.3,4,50
696

Furthermore, Cluster 2 and Cluster 4 alterations were
cumulatively acquired in 58% of ABC-like DLBCL and
60% of GCB-like DLBCL, respectively, further supporting
their respective overlap with the C5/MCD/MYD88 and
C4/ST2 subtypes of DLBCL. CNA within Cluster 5 were
cumulatively acquired at high but variable frequencies in all
of the subtypes, but showed subtype-specific patterns
within this cluster such as higher frequencies of 18q21 and
18q23 gains in ABC-like DLBCL, and higher frequencies of
chromosome 7 gains in GCB-like DLBCL and FL. B-NHL
tumors therefore cumulatively acquire co-associated sets of
genetic alterations in a manner that is characteristically
associated with histologically- and molecularly-defined
subsets of disease.

Discussion
By performing cross-sectional genomic profiling of a large
cohort of tumors, we have developed a resource of genes
and functional hallmarks that are recurrently targeted by
genetic alterations in B-NHL, and have shown that the
cumulative acquisition of combinations of genetic alterations are characteristic of histological and molecular subtypes of disease. Some of the functional hallmarks that we
identified have been previously appreciated, with a few
exceptions. For example, the mutation of genes with roles
haematologica | 2022; 107(3)

Patterns of genetic alterations in B-NHL

Figure 4. Subtype-specific clusters of co-occurring genetic alterations. The frequency (bar graph) and over- or under-representation (blue to red scale) of mutations
and structural alterations is shown on the left for Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. The correlation
matrix of co-associated (green) and mutually exclusive (purple) relationships was clustered to identify seven groups of co-occurring genetic alterations that were predominantly over-represented in a single subtype of B-cell non-Hodgkin lymphoma. BL: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma
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Figure 5. Subtype-specific patterns of BAF complex mutations. (A) An oncoplot shows the frequency of genetic alterations in genes that encode components of the
BAF complex. (B) A schematic of the BAF complex shows recurrently mutated genes, ARID1A, SMARCA4 and BCL7A, and the BCL11A gene that is targeted by 2p15
DNA copy number gains. (C-E) Lollipop plots show the distribution of mutations in the BAF components ARID1A (C), SMARCA4 (D), and BCL7A (E). (F) A heatplot
shows the location of chromosome 2p DNA copy number gains (red) ordered from highest DNA copy number (top) to lowest (bottom, copy number = 2.2). The BCL11A
gene is in the peak focal copy gain. BL: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma.

in epigenetic and transcriptional control of gene expression
are known to be a hallmark of FL52 and we observed that
96% of FL tumors possessed mutations in one or more of
the genes in this category. However, mutations within
these genes were also observed in the majority of BL,
DLBCL and MCL tumors, highlighting the conservation of
this functional hallmark across B-NHL subtypes. There are
subtype-specific patterns of chromatin-modifying gene
alterations, such as those that we highlighted for BAF complex mutations, but we suggest that the genetic deregulation of epigenetic and transcriptional control of gene
expression should be considered a general hallmark of BNHL. In addition, we suggest that the deregulation of the
ubiquitin proteasome system is a hallmark of B-NHL that
requires further investigation. Mutations in genes such as
KLHL637 and UBR539 have recently been shown to play an
important role in B-cell lymphoma, while the roles of other
frequently mutated genes such as DTX1 and SOCS1 have
not yet been functionally dissected. Furthermore, while the
nature of AID-driven mutations in genes such as DTX1 and
SOCS1 remain to be defined, other genes that are recurrently mutated by AID such as BCL7A53 and linker histone
genes54 have been shown to play driving roles in lymphomagenesis. Genetic deregulation of the ubiquitin proteasome system has the potential to influence the activity
or abundance of a range of substrate proteins, and represents a current gap in our knowledge of B-NHL etiology.
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The role of cooperative interactions between co-occurring genetic alterations is also an emerging field that
requires further investigation. These interactions are not
uncommon in cancer,55 and have been recently highlighted
in DLBCL,3,4 but our data show that they are pervasive and
characteristic features of the B-NHL genetic landscape.
Cooperation between co-associated genetic alterations
identified in this study requires formal validation in cell
lines and/or animal models. However, there are many
instances in which co-occurring genetic alterations that we
observed have already been shown to cooperate in lymphomagenesis. In addition to the aforementioned example
of MYD88 and CD79B mutations, transgenic mouse models of Ezh2 activating mutations or conditional deletion of
Crebbp or Kmt2d have shown that these events are not
alone sufficient for lymphomagenesis.56-61 We and others
have observed a co-association between mutation of these
genes and BCL2 translocations,14,62 and the addition of a Bcl2
transgene to these murine models indeed promoted lymphoma at a significantly higher rate than that observed with
the Bcl2 transgene alone.56-61 These genetic alterations are
therefore significantly more lymphomagenic in combination than they are alone, which provides proof of principle
that a cooperative relationship exists between these cooccurring genetic alterations. Future studies focusing on
other co-occurring mutations, such as MYC translocation
and SMARCA4 mutation in BL, CREBBP and KMT2D
haematologica | 2022; 107(3)
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B

Figure 6. Cumulative acquisition of co-occurring genetic alterations. (A) An oncoplot shows the presence or absence of genetic alterations according to their clusters of co-association in molecularly-defined Burkitt lymphoma, activated Bcell-like diffuse large B-cell lymphoma (DLBCL), germinal center B-cell-like DLBCL, follicular lymphoma and mantle cell lymphoma with available gene expression microarray data. Shading shows histological or molecular subtypes with 50%
of tumors bearing 2 genetic alterations within a given cluster. (B) Bar plots shows the frequency of tumors with 2 genetic alterations from each cluster. mBL: molecularly-defined Burkitt lymphoma; ABC: activated B-cell-like DLBCL; COO:
cell of origin; GCB: germinal center B-cell-like DLBCL; FL: follicular lymphoma; MCL: mantle cell lymphoma.
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mutation in FL, TCF4 copy gain and MYD88 mutation in
DLBCL, and ATM mutation and RPL5 deletion in MCL,
should therefore be performed to further explore these concepts and define their underlying functional relationship.
We suggest that combinations of genetic alterations are
likely to recapitulate the biology of B-NHL more accurately
than are single gene models, and may reveal contextually
different functional roles of genetic alterations depending
on the co-occurring events.
The caveats regarding this study include the targeted
nature of the LymphoSeq platform which may preclude
consideration of a subset of important genes, the lack of
germline DNA for the majority of samples that may lead to
a small number of germ-line variants being falsely assigned
as somatic, and the sample size for any given histological
subtype being below that required to identify genes that are
mutated at low frequency. Nonetheless, these data represent the first broad cross-sectional analysis of multiple histological and molecular subtypes of B-NHL using the same
methodology and provide a framework of functional hallmarks and co-occurring genetic alterations that are enriched
within these subtypes of B-NHL. These functional hallmarks are genetically perturbed in the majority of B-NHL,
but our cross-sectional approach enabled us to elucidate
subtype-specific preferences for genetic alterations within
each functional hallmark. Furthermore, the subtype-specific clusters of co-occurring genetic alterations likely represent cooperative interactions that underpin the biology
of different subtypes of B-NHL. These combinations identify opportunities for moving from single-allele to multiallele designs in cell line or animal models to better understand the molecular etiology of B-NHL subtypes. Together,
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